Search

Drone technology opens the door to major changes and opportunities in our society. But this technology, like many others, needs to be administered and regulated to prevent potential harm to the public. Therefore, national and local governments around the world established regulations for operating drones, which bans drone use from specific locations or limits their operation to qualified drone pilots only. This study reviews the types of restrictions on drone use that are specified in federal drone regulations for the US, the UK, and France, and in state regulations for the US. The study also maps restricted areas and assesses compliance with these regulations by analyzing the spatial contribution patterns to three crowd-sourced drone portals, namely SkyPixel, Flickr, and DroneSpot, relative to restricted areas. The analysis is performed both at the national level and at the state/regional level within each of the three countries, where statistical tests are conducted to compare compliance rates between the three drone portals. This study provides new insight into drone users' awareness of and compliance with drone regulations. This can help governments to tailor information campaigns for increased awareness of drone regulations among drone users and to determine where increased control and enforcement of drone regulations is necessary. [ABSTRACT FROM AUTHOR]

We explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in patients with atopic dermatitis (AD) treated in routine clinical practice. Adults with moderate-to-severe AD treated with baricitinib in clinical practice for ≥4 weeks in France, Germany, and the UK completed a one-time online survey under market research methodologies. Treatment satisfaction was assessed using a Likert scale and abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients reported demographic, disease, and treatment information. Data were analyzed descriptively. The survey was completed by 170 patients with a mean age of 39.3 years (SD = 13.5), 59% (n = 101) were female. At baricitinib initiation, 79% rated their AD as "Severe", yet 28% reported body surface area (BSA) involvement ≥10%. Most were "Satisfied" or "Very satisfied" (76%/18%) with baricitinib, with high rates reported for controlling itch (36%/56%). Itch improvements were noted by 97% of patients. Some tapered/stopped (50%/32%) topical corticosteroid use, aligned with reported improvements on the patient global assessment and BSA. Mean TSQM-9 convenience score was 78.0 (SD = 14.0). Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib's effect in controlling AD symptoms. [ABSTRACT FROM AUTHOR]